The therapeutic dose found in phase I/II clinical trials for head and neck cancer with redaporfin-vascular-PDT (0.75 mg/kg, DLI = 15 min, 50 J/cm2 @ 130 mW/cm2) [20] is the same as the optimal dose found in preclinical studies with BALB/c mice bearing CT26.WT tumours (0.75 mg/kg, DLI = 15 min, 50 J/cm2, 130 mW/cm2, 13 mm diameter illumination circle), that cured 86% of the animals and led to the majority of cured animals rejecting re-challenge with the same tumour model [14]. This evidence concerns the gene DDX53 and head and neck cancer.